These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 4337075)

  • 1. [The present status of the question of the mechanism of action of sulfanilamide hypoglycemic preparations and several aspects of their use in the treatment of diabetes mellitus].
    Mordkovskaia NM
    Probl Endokrinol (Mosk); 1971; 17(5):121-5. PubMed ID: 4337075
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pathophysiology of diabetes mellitus type 2 and the mechanism of action and indications for using hypoglycemic sulfonylurea derivatives].
    Tatoń J; Koliński P
    Pol Tyg Lek; 1985 May; 40(18):505-11. PubMed ID: 3892513
    [No Abstract]   [Full Text] [Related]  

  • 3. [Mode of action of oral hypoglycemic sulfonylureas].
    Paes E
    Rev Iber Endocrinol; 1972; 19(113):449-59. PubMed ID: 4563178
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of antidiabetic sulfanilamide preparations].
    Genes SG
    Ter Arkh; 1970 Jan; 42(1):15-21. PubMed ID: 5446836
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide).
    Loubatiéres A; Mariani MM; Ribes G; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200675
    [No Abstract]   [Full Text] [Related]  

  • 6. [Current concepts of the pancreatic and extrapancreatic mechanisms of the action of peroral hypoglycemic sulfonylurea preparations].
    Poltorak VV; Gladkikh AI
    Probl Endokrinol (Mosk); 1985; 31(2):76-85. PubMed ID: 2859589
    [No Abstract]   [Full Text] [Related]  

  • 7. Glibenclamide: a review.
    Drugs; 1971; 1(2):116-40. PubMed ID: 5004340
    [No Abstract]   [Full Text] [Related]  

  • 8. Complementary arguments in favor of the betacytotrophic action of the hypglycemic sulfonamides.
    Loubatières AL
    Adv Metab Disord; 1970; 1():Suppl 1:411+. PubMed ID: 4911189
    [No Abstract]   [Full Text] [Related]  

  • 9. Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents?
    Marble A
    Drugs; 1971; 1(2):109-15. PubMed ID: 4999930
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanism of action of the second-generation sulfonylurea glipizide.
    Lebovitz HE; Feinglos MN
    Am J Med; 1983 Nov; 75(5B):46-54. PubMed ID: 6369967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New horizons in our knowledge of diabetes mellitus.
    Levine R
    J Am Geriatr Soc; 1971 Nov; 19(11):897-908. PubMed ID: 4949263
    [No Abstract]   [Full Text] [Related]  

  • 12. Blockade of insulin secretion by mannoheptulose.
    Simon E; Frenkel G; Kraicer PF
    Isr J Med Sci; 1972 Jun; 8(6):743-52. PubMed ID: 4626312
    [No Abstract]   [Full Text] [Related]  

  • 13. New pharmacologic approaches to the treatment of diabetes.
    Johnson DG; Bressler R
    Spec Top Endocrinol Metab; 1984; 6():163-92. PubMed ID: 6151747
    [No Abstract]   [Full Text] [Related]  

  • 14. Different amounts of insulin secretion following an equal total decrease of blood glucose as an indication of possible extrapancreatic activities of different sulfonylurea drugs.
    Beyer J; Haupt E; Cordes U; Kutschera J; Schöffling K
    Horm Metab Res; 1973 Jan; 5(1):9-13. PubMed ID: 4196346
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical experience with the blood sugar reducing sulfonamide derivative glisoxepide].
    Petzoldt R; Riedesel G; Ramrath M; Grabs V; Haupt E; Schwedes U; Ewald W; Beyer J; Schöffling K
    Arzneimittelforschung; 1974 Mar; 24(0):429-32. PubMed ID: 4603399
    [No Abstract]   [Full Text] [Related]  

  • 16. Glucose tolerance in diabetes mellitus during treatment with the sulfonylurea hypoglycemic agents.
    Herman JB
    Isr J Med Sci; 1966; 2(6):733-7. PubMed ID: 5956689
    [No Abstract]   [Full Text] [Related]  

  • 17. [Insulin secretion in the clinical stages of diabetes (with glucose tolerance test abnormalities)].
    Vague P; Vague J
    Journ Annu Diabetol Hotel Dieu; 1972; 13(0):55-65. PubMed ID: 4605752
    [No Abstract]   [Full Text] [Related]  

  • 18. Potentiating effects of combined usage of three sulfonylurea drugs on the occurrence of alloxan diabetes in rats.
    Katsumata K; Katsumata Y; Ozawa T; Katsumata K
    Horm Metab Res; 1993 Feb; 25(2):125-6. PubMed ID: 8458609
    [No Abstract]   [Full Text] [Related]  

  • 19. [Physiological and pharmacological aspects of the central role of the pancreas in the mode of action of hypoglycemic sulfonamides].
    Loubatières A
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():216-55. PubMed ID: 4906020
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview.
    Beck-Nielsen H; Hother-Nielsen O; Pedersen O
    Diabet Med; 1988 Oct; 5(7):613-20. PubMed ID: 2975544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.